You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Sensitive Measurement of Cardiac Troponin I at Point of Care: The Silicon BioDevi

    SBC: SILICON BIODEVICES, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Acute myocardial infarction (MI), aka heart attack is the biggest killer in the western world and is the cause of death for nearly 500,000 Americans each year. The symptoms of MI can be vague and non-specific; for this reason 6 to 9 million adults present to hospital Emergency Departments in the US and are worked up for suspected MI annually. Advances in card ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Estrogen Receptor B Selective Receptor Agonists to Treat Neuropath

    SBC: ACADIA PHARMACEUTICALS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Neuropathic pain is a serious neurological disorder affecting approximately 1.8 million people in the United States. It is refractory to standard analgesic therapies, with all current neuropathic pain drugs providing relief to approximately 30% of patients. In addition, these drugs all have significant side effects. Consequently there is a clear unmet medical ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. IGF::OT::IGF Contract Title: SBIR Phase II Topic 324 Development of an Imaging Agent Targeting Sialyl Lewis A;

    SBC: MABVAX THERAPEUTICS, INC.            Topic: NCI

    The carbohydrate antigen sialyl-Lewis a (sLea), also known as CA19.9, is widely expressed in pancreatic cancer (PC), and serum CA19.9 expression is used as a tumor marker in PC. sLea serves as a ligand for E-selectin adhesion molecules and over-expression of sLea may be a key event in invasion and metastasis. We have generated a series of fully human monoclonal antibodies (mAb) and 5B1 (IgG1/λ) w ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Stand-off Detection of Alternative Signatures of Radiation

    SBC: Tanner Research, Inc.            Topic: DTRA122014

    Prevention of the smuggling of special nuclear materials (SNMs) and other radioactive material into the United States is a key national security objective. It is desirable to have a system capable of stand-off detection to monitor and rapidly alert the presence of covert nuclear materials. In Phase I, Tanner in collaboration with the University of New Mexico have established the method of inferrin ...

    SBIR Phase II 2014 Department of DefenseDefense Threat Reduction Agency
  5. Development of breakthrough intra-operative detector and imaging system for parat

    SBC: Anasys Instruments Corp.            Topic: 102

    DESCRIPTION provided by applicant There are parathyroid glands in the neck and they are responsible for the production of parathyroid hormone which maintains calcium homeostasis throughout the body They are difficult to identify relative to the other tissues in the neck such s lymph nodes fat thyroid etc This has resulted in the incidence of accidental parathyroid removal ranging from ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. A Rapid assay for RNA targeted drugs: Instrumentation Supplement

    SBC: NUBAD LLC            Topic: 300

    DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Assessing the Bite Counter as a Tool for Food Intake Monitoring: Phase II

    SBC: BITE TECHNOLOGIES, LLC            Topic: 300

    DESCRIPTION provided by applicant Self monitoring has been described as the andquot cornerstone of the behavioral treatment of obesityandquot Consistent self monitoring of energy intake is associated with improved dietary adherence and weight loss and maintenance The problem is that individuals are notoriously bad at self monitoring their intake and suffer from an underreporting bias The s ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. A Quantitative Optical Sensor to Monitor Tumor Vascular Physiology

    SBC: Zenalux Biomedical, Inc.            Topic: 102

    DESCRIPTION provided by applicant In there were new cases of head and neck cancers HNC in the United States Early detection of new and locally recurrent cancers is clinically important to reduce not only cancer related mortality but also treatment associated morbidity as it impacts multiple organ functions including respiration olfaction hearing eating swallowing and speak ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The leading cause of mortality in patients with cystic fibrosis CF is pulmonary failure from lung infections and the predominant organism isolated from these infections is the bacterium Pseudomonas aeruginosa Lung infections of CF patients persist over the lifetime of the patients and are impossible to eradicate due to the ability of bacteria to form biofi ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Human monoclonal antibodies for prevention of S. aureus infections

    SBC: SORRENTO THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Using mouse monoclonal antibodies mAbs raised against the mediators of quorum sensing QS the Auto Inducing Peptides AIPs researchers at The Scripps Research Institute TSRI have demonstrated that S aureus infections can be prevented in animal challenge models This approach known as quorum quenching QQ is unique in at least two significant ways fi ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government